Newsroom

SENDAI, Japan--(BUSINESS WIRE)--RevolKa Ltd. (RevolKa), a venture-backed biotech company providing an advanced AI protein engineering technology platform, called aiProtein®, is pleased to announce the official global launch of RevoAb®, an innovative and quick online service for antibody sequence optimization to solve challenges in physicochemical properties, especially antibody yields. RevoAb®: The Next-Gen AI Antibody Design Since December 2023, RevolKa has provided an antibody optimization se...

SCHAFFHAUSEN, Switzerland--(BUSINESS WIRE)--Versigent PLC (NYSE: VGNT) today announced the completion of its separation from Aptiv PLC (NYSE: APTV) and its launch as an independent, publicly traded company. Versigent’s shares will begin trading on the New York Stock Exchange (NYSE) under the ticker symbol “VGNT” today where members of the Company’s leadership team are scheduled to ring the Opening Bell. Versigent is a global leader in the design, manufacturing, and delivery of low- and high-vol...

NEW YORK--(BUSINESS WIRE)--For years, Susan watched her two children collapse without warning. Episodes of sudden, full-body muscle weakness that came and went — sometimes lasting minutes, sometimes hours. Between episodes, they looked like any other healthy kids. And that was the problem. Susan, a single mother in a small town in New Zealand, took her children to doctor after doctor. Blood panels came back normal. She was told the symptoms were stress-related. No referrals. No follow-up. No an...

NEW YORK--(BUSINESS WIRE)--Per anni, Susan vedeva i suoi due figli crollare senza preavviso. Episodi di improvvisa debolezza muscolare in tutto il corpo — a volte duravano minuti, a volte ore. Tra un episodio e l'altro, sembravano bambini sani come gli altri. Ed era proprio questo il problema. Susan, una madre single in una piccola città della Nuova Zelanda, ha portato i suoi figli da molti medici. I valori del sangue erano nella norma. Le è stato detto che i sintomi erano legati allo stress. N...

MARLBOROUGH, Massachusetts--(BUSINESS WIRE)--ExaGrid®, el principal proveedor independiente de almacenamiento para copias de seguridad del mundo, especializado en servicios de almacenamiento por niveles con la seguridad más completa y un sistema de retención con bloqueo temporal con IA para asegurar la recuperación ante ransomware, ha anunciado hoy que ha sido nominada en 11 categorías de los premios anuales Network Computing Awards. ExaGrid ya es el finalista en las categorías siguientes: Prod...

マサチューセッツ州マールボロ--(BUSINESS WIRE)--（ビジネスワイヤ） -- 階層型バックアップストレージを提供し、ランサムウェア復旧のための最も包括的なセキュリティーおよびAI搭載リテンションタイムロック機能を備える世界最大の独立系バックアップストレージベンダーであるエクサグリッド®は、年次開催のNetwork Computing Awardsにおいて11部門でノミネートされたことを発表しました。 エクサグリッドは、以下の各部門においてファイナリストに選出されました。 Data Protection Product of the Year（データ保護製品オブザイヤー） The Return On Investment Award（投資収益率賞） Air Gapped Ransomware Recovery Product of the Year（エアギャップ型ランサムウェア復旧製品オブザイヤー） Storage Product of the Year（ストレージ製品オブザイヤー） Hardware Product of the Year（ハードウエア製品オブザイヤー）...

STILLWATER, Minnesota et TEL-AVIV, Israël--(BUSINESS WIRE)--Sub-Q Bionics, une entreprise de dispositifs médicaux qui développe des solutions de nouvelle génération pour améliorer la prise en charge des patients atteints de lymphœdème, a annoncé aujourd’hui la clôture réussie de son tour de table de préamorçage d’un montant de 1,5 million USD. Ce tour de table comprend des investissements de la Mayo Clinic et de Yeda, la société de transfert de technologie de l’Institut Weizmann des Sciences, a...

STILLWATER, Minnesota e TEL AVIV, Israele--(BUSINESS WIRE)--Sub-Q Bionics, azienda produttrice di dispositivi medici che sviluppa soluzioni di prossima generazione per migliorare la cura di pazienti affetti da linfedema, ha annunciato oggi il closing del suo round di finanziamento di fase pre-seed di 1,5 milioni di dollari. Il round include un investimento di Mayo Clinic e Yeda, l'azienda di trasferimento tecnologico del Weizmann Institute of Science, nonché di diversi investitori privati. Anch...

STILLWATER, Minn. & TEL AVIV, Israël--(BUSINESS WIRE)--Sub-Q Bionics, een bedrijf dat medische hulpmiddelen maakt en oplossingen van de nieuwe generatie ontwikkelt om de zorgverlening te verbeteren voor patiënten die met lymfoedeem leven, kondigde vandaag de succesvolle sluiting aan van haar pre-seed financieringsronde van $1,5 miljoen. De financieringsronde omvat investeringen van Mayo Clinic en Yeda, het technologietransferbedrijf van de Weizmann Institute of Science, evenals van verschillend...

STILLWATER, Minn. & TEL AVIV, Israel--(BUSINESS WIRE)--Sub-Q Bionics, ein Medizintechnikunternehmen, das Lösungen der nächsten Generation zur Verbesserung der Versorgung von Patienten mit Lymphödemen entwickelt, gab heute den erfolgreichen Abschluss seiner Pre-Seed-Finanzierungsrunde in Höhe von 1,5 Millionen USD bekannt. An dieser Finanzierungsrunde beteiligen sich die Mayo Clinic und Yeda, die Technologietransfergesellschaft des Weizmann Institute of Science, sowie mehrere private Investoren....